Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent

Science

Volumn 355, Issue 6332, 2017, Pages 1423-1427

  Kamphorst, Alice O ^a   Wieland, Andreas ^a   Nasti, Tahseen ^a   Yang, Shu ^a,b,h   Zhang, Ruan ^c   Barber, Daniel L ^a,d   Konieczny, Bogumila T ^a   Daugherty, Candace Z ^a   Koenig, Lydia ^a   Yu, Ke ^a   Sica, Gabriel L ^a   Sharpe, Arlene H ^e   Freeman, Gordon J ^f   Blazar, Bruce R ^g   Turka, Laurence A ^c   Owonikoko, Taofeek K ^a   Pillai, Rathi N ^a   Ramalingam, Suresh S ^a   Araki, Koichi ^a   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Central South University   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; B7 ANTIGEN; CD28 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

BLOOD; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; INFECTIVITY; MOLECULAR ANALYSIS; TUMOR; VIRAL DISEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTIC CHORIOMENINGITIS; METABOLISM;

MUS;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; GENE DELETION; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTIC CHORIOMENINGITIS; METABOLIC NETWORKS AND PATHWAYS; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85015679329     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf0683     Document Type: Article

References (25)

1. D. S. Chen, I. Mellman, Immunity 39, 1-10 (2013).
2. M. K. Callahan, M. A. Postow, J. D. Wolchok, Immunity 44, 1069-1078 (2016).
3. K. E. Pauken, E. J. Wherry, Trends Immunol. 36, 265-276 (2015).
4. R. J. Greenwald, G. J. Freeman, A. H. Sharpe, Annu. Rev. Immunol. 23, 515-548 (2005).
5. J. H. Esensten, Y. A. Helou, G. Chopra, A. Weiss, J. A. Bluestone, Immunity 44, 973-988 (2016).
6. T. M. Kündig et al., Immunity 5, 41-52 (1996).
7. J. Eberlein et al., J. Virol. 86, 1955-1970 (2012).
8. T. L. Floyd et al., J. Immunol. 186, 2033-2041 (2011).
9. M. Matloubian, R. J. Concepcion, R. Ahmed, J. Virol. 68, 8056-8063 (1994).
10. D. L. Barber et al., Nature 439, 682-687 (2006).
11. M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, G. J. Freeman, Immunity 27, 111-122 (2007).
12. A. M. Paterson et al., J. Immunol. 187, 1097-1105 (2011).
13. M. E. Keir, M. J. Butte, G. J. Freeman, A. H. Sharpe, Annu. Rev. Immunol. 26, 677-704 (2008).
14. B. Homet Moreno et al., Cancer Immunol. Res. 4, 845-857 (2016).
15. J. D. Miller et al., Immunity 28, 710-722 (2008).
16. A. O. Kamphorst et al., Cancer Res. 75 (15 Supplement), 1317 (2015).
17. N. P. Weng, A. N. Akbar, J. Goronzy, Trends Immunol. 30, 306-312 (2009).
18. Y. Li et al., J. Immunol. 184, 452-465 (2010).
19. G. Filaci et al., J. Immunol. 179, 4323-4334 (2007).
20. S. J. Im et al., Nature 537, 417-421 (2016).
21. H. Salmon et al., Immunity 44, 924-938 (2016).
22. S. Spranger, R. Bao, T. F. Gajewski, Nature 523, 231-235 (2015).
23. S. N. Mueller et al., J. Clin. Invest. 120, 2508-2515 (2010).
24. P. C. Tumeh et al., Nature 515, 568-571 (2014).
25. E. Hui et al., Science 355, 1428 (2017).